Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dorian Jones

Gastroenterology East Lansing, MI Medical Doctor

NPI 1508157702 CMS profile 804724

1650 Ramblewood Dr Ste 200, East Lansing, MI 48823

Open in the dashboard

General payments

$11,592

687 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dorian Jones of East Lansing, MI is reported in the CMS Open Payments database as having received $11,592 across 687 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,129 158
2024 General $2,194 124
2023 General $2,320 116
2022 General $1,797 118
2021 General $827 71
2020 General $600 48
2019 General $726 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dorian Jones
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Dorian Jones were reported at $3,129. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Dorian Jones Gastroenterology median Middle half National median
2019 $726 $417 $126–$1,100 $163
2020 $600 $224 $74–$624 $114
2021 $827 $352 $106–$1,054 $132
2022 $1,797 $448 $129–$1,270 $149
2023 $2,320 $533 $150–$1,390 $160
2024 $2,194 $605 $160–$1,606 $164
2025 $3,129 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,547 180 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,735 88 payments
  3. Janssen Biotech, Inc. $1,366 78 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,330 83 payments
  5. Pfizer Inc. $585 33 payments
  6. Gilead Sciences, Inc. $564 29 payments
  7. Celgene Corporation $521 44 payments
  8. Regeneron Healthcare Solutions, Inc. $500 24 payments
  9. Genzyme Corporation $305 14 payments
  10. Lilly USA, LLC $265 11 payments
  11. Other $1,872 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,416 678 payments
  2. Education $176 9 payments
Products named General payments · program years 2019–2025
  1. ENTYVIO $1,344 64 payments
  2. RINVOQ $1,303 64 payments
  3. XIFAXAN $1,130 64 payments
  4. STELARA $881 58 payments
  5. SKYRIZI Immunology $580 30 payments
  6. ZEPOSIA $540 45 payments
  7. TREMFYA $539 23 payments
  8. XELJANZ $508 29 payments
  9. HUMIRA $388 28 payments
  10. SKYRIZI Immunology $387 22 payments
  11. Other $5,232 337 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

644

Median for Internal Medicine: 777

Drug cost

$1,722,200

Median for Internal Medicine: $73,373

Branded share of claims

78.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 53 $1,443,625
Humira(Cf) Pen Adalimumab Brand 15 $100,692
Xeljanz Tofacitinib Citrate Brand 14 $76,546
Cimzia (2 Pack) Certolizumab Pegol Brand 12 $64,438
Linzess Linaclotide Brand 21 $15,320
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 65 $10,349
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 175 $3,626
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 126 $2,558
Pantoprazole Sodium Generic 71 $1,940
Budesonide Dr Budesonide Brand 11 $1,272

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$101,669

Medicare's payments for the services billed

Medicare patients

317

Average age 71

Services billed

3,607

171 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 53%
Depression 32%
Diabetes 31%
Chronic kidney disease 29%
Ischemic heart disease 25%
Atrial fibrillation 22%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $172
  • Regeneron Healthcare Solutions, Inc. $143
$315 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $230
$230 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $179
$179 — —
SKYRIZI
  • AbbVie, Inc. $171
$171 — —
STELARA
  • Janssen Biotech, Inc. $170
$170 53 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

687 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record